GB Sciences (STU:18C) Debt-to-Equity : -0.31 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is GB Sciences Debt-to-Equity?

GB Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.32 Mil. GB Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.07 Mil. GB Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-4.45 Mil. GB Sciences's debt to equity for the quarter that ended in Dec. 2023 was -0.31.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for GB Sciences's Debt-to-Equity or its related term are showing as below:

STU:18C' s Debt-to-Equity Range Over the Past 10 Years
Min: -107.01 Med: -0.31 Max: 3.23
Current: -0.31

During the past 13 years, the highest Debt-to-Equity Ratio of GB Sciences was 3.23. The lowest was -107.01. And the median was -0.31.

STU:18C's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs STU:18C: -0.31

GB Sciences Debt-to-Equity Historical Data

The historical data trend for GB Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Debt-to-Equity Chart

GB Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.74

-106.53

-3.02

-0.78

-0.32

GB Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.87	-0.32	-0.31	-0.32	-0.31

Competitive Comparison of GB Sciences's Debt-to-Equity

For the Biotechnology subindustry, GB Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GB Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where GB Sciences's Debt-to-Equity falls into.

GB Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

GB Sciences's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.304	+	0)	/	-4.116
	=	-0.32

GB Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.318	+	0.069)	/	-4.445
	=	-0.31

GB Sciences (STU:18C) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

GB Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of GB Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GB Sciences (STU:18C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (STU:18C) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GBLX:USA

Address

9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148

Website

https://www.gbsciences.com

GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.

GB Sciences (STU:18C) Headlines

No Headlines